Table 1 Baseline characteristics of the study population
No transfer (%) | Transfer (%) | Total (%) | P-value | ||
|---|---|---|---|---|---|
N | 4434 | 6839 | 11,273 | ||
Agea | <68 | 2068 (46.64) | 3275 (47.89) | 5343 (47.40) | 0.198 |
> = 68 | 2366 (53.36) | 3564 (52.11) | 5930 (52.60) | ||
Sex | Male | 2299 (51.85) | 3548 (51.88) | 5847 (51.87) | 0.976 |
Female | 2135 (48.15) | 3291 (48.12) | 5426 (48.13) | ||
Stage | 0, I, II, IIIa | 1611 (36.33) | 3450 (50.48) | 5061 (44.89) | <0.000 |
IIIb, IV | 2799 (63.13) | 3347 (48.94) | 6146 (54.52) | ||
Missing | 24 (0.54) | 42 (0.61) | 66 (0.59) | ||
Co-morbidity (CCI) | 0 | 2333 (52.62) | 3479 (50.87) | 5812 (51.56) | 0.156 |
1 | 1829 (41.25) | 2904 (42.46) | 4722 (41.99) | ||
>1 | 272 (6.13) | 456 (6.67) | 728 (6.46) | ||
Treatment | Curative | 1287 (29.03) | 3435 (50.08) | 4712 (41.80) | <0.000 |
Palliative | 3147 (70.97) | 3414 (49.92) | 6561 (58.20) | ||
ECOG | 0 | 1618 (36.49) | 3068 (44.86) | 4686 (41.57) | <0.000 |
1 | 1705 (38.45) | 2299 (33.62) | 4004 (35.52) | ||
>1 | 1111 (25.06) | 1472 (21.52) | 2583 (22.91) | ||
Year | 2008 | 1259 (37.24) | 747 (62.76) | 2006 (100) | <0.000 |
2009 | 1408 (33.65) | 714 (66.35) | 2122 (100) | ||
2010 | 1452 (37.09) | 856 (62.91) | 2308 (100) | ||
2011 | 1504 (40.48) | 1023 (59.52) | 2527 (100) | ||
2012 | 1216 (47.36) | 1094 (52.64) | 2310 (100) | ||
FEV1 N (Mean, sd) | 3842 (1.83,0.85) | 6363 (1.96, 0.89) | 10,205 (1.91,0.87) | <0.000 | |
Days from referral to treatment Mean(sd) | 35.59 (14.58) | 40.19 (15.68) | 38.38 (15.42) | <0.000 | |
Days from referral to diagnosis Mean (sd) | 20.26 (11.59) | 22.26 (12.43) | 21.47 (12.13) | <0.000 | |
Days from diagnosis to treatment Mean (sd) | 15.33 (9.70) | 17.93 (11.09) | 16.91 (10.64) | <0.000 | |